Point72 Asset Management
REGN icon

Point72 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Sell
2,175
-260,352
-99% -$199M ﹤0.01% 2436
2025
Q4 		$203M Buy
262,527
+61,028
+30% +$41.4M 0.23% 52
2025
Q3 		$113M Buy
201,499
+58,391
+41% +$33M 0.19% 105
2025
Q2 		$75.1M Buy
+143,108
New +$79.9M 0.15% 164
2024
Q3 		– Sell
-22,871
Closed -$25.5M – 2279
2024
Q2 		$24M Buy
+22,871
New +$22.2M 0.06% 356
2023
Q4 		– Sell
-1,407
Closed -$1.16M – 2702
2023
Q3 		$1.16M Buy
+1,407
New +$1.11M ﹤0.01% 1284
2021
Q3 		– Sell
-188,700
Closed -$105M – 1206
2021
Q2 		$105M Buy
+188,700
New +$95.6M 0.47% 35
2020
Q3 		– Sell
-53,609
Closed -$33.4M – 1070
2020
Q2 		$33.4M Buy
+53,609
New +$30.4M 0.22% 128
2019
Q4 		– Sell
-440,940
Closed -$122M – 1204
2019
Q3 		$122M Sell
440,940
-42,905
-9% -$12.7M 0.75% 19
2019
Q2 		$151M Buy
+483,845
New +$161M 0.79% 17
2019
Q1 		– Sell
-168,644
Closed -$63M – 1195
2018
Q4 		$63M Buy
+168,644
New +$61.7M 0.31% 89
2018
Q3 		– Sell
-27,700
Closed -$9.56M – 1190
2018
Q2 		$9.56M Sell
27,700
-171,400
-86% -$53.6M 0.04% 451
2018
Q1 		$68.6M Sell
199,100
-282,254
-59% -$98.2M 0.29% 95
2017
Q4 		$181M Buy
+481,354
New +$195M 0.78% 15
2017
Q2 		– Sell
-70,000
Closed -$27.1M – 978
2017
Q1 		$27.1M Buy
+70,000
New +$25.9M 0.15% 186
2016
Q2 		– Sell
-109,700
Closed -$39.5M – 849
2016
Q1 		$39.5M Buy
+109,700
New +$45.2M 0.3% 81
2014
Q4 		– Sell
-23,600
Closed -$8.51M – 774
2014
Q3 		$8.51M Buy
23,600
+9,100
+63% +$3.05M 0.06% 307
2014
Q2 		$4.1M Buy
+14,500
New +$4.3M 0.03% 487

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Asset Management's REGN Position: Q1 2026 in Review

Point72 Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 99% in Q1 2026, selling an estimated $199M and leaving 2,175 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Point72 Asset Management first reported a position in REGN in Q2 2014 and has held it in 18 quarters since. The position peaked at $203M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Point72 Asset Management held 2,175 shares of Regeneron Pharmaceuticals worth $1.68M as of Q1 2026.
  • Point72 Asset Management sold 260,352 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $199M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2436 holding.
  • Point72 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 18 quarters since.
  • Point72 Asset Management's Regeneron Pharmaceuticals position peaked at $203M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.